89BIO INC. - COMMON STOCK
11.06
21-فبراير-25 16:45:00
15 متأخرة بدقائق
الأسهم
+0.10
+0.91%
نطاق اليوم
10.88 - 11.23
ISIN
N/A
المصدر
NASDAQ
-
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
10 يونيو 2021 08:30:00 بحسب Nasdaq GlobeNewswire
-
89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
12 مايو 2021 16:05:00 بحسب Nasdaq GlobeNewswire
-
89bio to Present at Upcoming Investor Conferences
05 مايو 2021 08:00:01 بحسب Nasdaq GlobeNewswire
-
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH
05 أبريل 2021 08:00:01 بحسب Nasdaq GlobeNewswire
-
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
24 مارس 2021 16:05:00 بحسب Nasdaq GlobeNewswire
-
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
20 مارس 2021 11:00:00 بحسب Nasdaq GlobeNewswire
-
89bio to Present at the Oppenheimer 31st Annual Healthcare Conference
11 مارس 2021 08:00:01 بحسب Nasdaq GlobeNewswire
-
89bio to Participate in the H.C. Wainwright Global Life Sciences Conference
03 مارس 2021 08:00:02 بحسب Nasdaq GlobeNewswire
-
89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference
24 فبراير 2021 08:00:01 بحسب Nasdaq GlobeNewswire
-
89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference
18 فبراير 2021 08:00:02 بحسب Nasdaq GlobeNewswire
-
89bio Provides Business Outlook for 2021
05 يناير 2021 08:00:02 بحسب Nasdaq GlobeNewswire
-
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
04 يناير 2021 08:00:01 بحسب Nasdaq GlobeNewswire